Xocova (ensitrelvir)
Shionogi
ApprovedMay 29, 2026
Marketer take
An oral COVID-19 post-exposure prevention option, unlike treatment-focused Paxlovid, so the audience extends to primary care, urgent care and pharmacies, with seasonal demand.
- Sponsor company
- Shionogi
- Indication
- To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
- Therapeutic area
- Infectious disease
- Event
- FDA approval
- Date
- May 29, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?